GlaxoSmithKline (NYSE: GSK) has extended its $2.6 billion takeover offer for Human Genome Sciences (NASDAQ: HGSI) until the end of this month. The original tender period expired on June 7. GKS has now extended the tender period to June 29.
Continue reading GlaxoSmithKline Extends Offer for Human Genome Sciences (GSK, HGSI)